Processa Pharmaceuticals (NASDAQ: PCSA) is one of 888 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Processa Pharmaceuticals to similar companies based on the strength of its earnings, analyst recommendations, valuation, risk, institutional ownership, profitability and dividends.
Earnings and Valuation
This table compares Processa Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Processa Pharmaceuticals||N/A||-$14.41 million||-5.93|
|Processa Pharmaceuticals Competitors||$1.70 billion||$122.33 million||-2.41|
Volatility and Risk
Processa Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Processa Pharmaceuticals’ rivals have a beta of 1.26, suggesting that their average stock price is 26% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Processa Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Processa Pharmaceuticals Competitors||5014||18584||40482||778||2.57|
Processa Pharmaceuticals presently has a consensus target price of $20.00, suggesting a potential upside of 144.20%. As a group, “Pharmaceutical preparations” companies have a potential upside of 56.88%. Given Processa Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Processa Pharmaceuticals is more favorable than its rivals.
Institutional & Insider Ownership
8.8% of Processa Pharmaceuticals shares are held by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 25.7% of Processa Pharmaceuticals shares are held by insiders. Comparatively, 14.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Processa Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Processa Pharmaceuticals Competitors||-3,674.63%||-115.85%||-26.81%|
Processa Pharmaceuticals rivals beat Processa Pharmaceuticals on 7 of the 13 factors compared.
Processa Pharmaceuticals Company Profile
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its lead product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.